• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.

    5/13/26 9:19:15 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TERN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Terns Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    880881107

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    880881107


    1Names of Reporting Persons

    Adage Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,124,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,124,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,124,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.84 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP Number(s):
    880881107


    1Names of Reporting Persons

    Robert Atchinson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,124,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,124,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,124,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.84 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP Number(s):
    880881107


    1Names of Reporting Persons

    Phillip Gross
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,124,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,124,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,124,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.84 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Terns Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    1065 East Hillsdale Blvd., Suite 100, Foster City, CA, 94404
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Terns Pharmaceuticals, Inc., a Delaware corporation (the "Company"), directly held by ACP; (ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and (iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
    (c)Citizenship:

    ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    880881107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 115,413,392 shares of Common Stock outstanding as of March 27, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.
    (b)Percent of class:

    1.84%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a).
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Adage Capital Management, L.P.
     
    Signature:/s/ Robert Atchinson
    Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
    Date:05/13/2026
     
    Robert Atchinson
     
    Signature:/s/ Robert Atchinson
    Name/Title:Robert Atchinson, individually
    Date:05/13/2026
     
    Phillip Gross
     
    Signature:/s/ Phillip Gross
    Name/Title:Phillip Gross, individually
    Date:05/13/2026
    Get the next $TERN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TERN

    DatePrice TargetRatingAnalyst
    3/25/2026Buy → Neutral
    H.C. Wainwright
    2/9/2026$58.00Outperform
    Leerink Partners
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    11/3/2025Mkt Perform → Outperform
    William Blair
    10/15/2025$20.00Buy
    Truist
    9/17/2025$15.00Overweight
    Barclays
    9/4/2025Neutral
    H.C. Wainwright
    2/28/2025Mkt Perform
    William Blair
    More analyst ratings

    $TERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

    Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck's oncology pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN). "The Terns acquisition reflects Merck's continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients," said Robert M. Davis, chairman and chief executive officer, Merck. "We believe TERN‑701 has the potential to become a differentiated treatment option for certain patients with chronic myeloid leu

    5/5/26 8:45:00 AM ET
    $MRK
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

    FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs. "There remains an urgent need for CML treatments that offer improved efficacy, safety, and tolerability over current therapies," said Scott Harris, chief development and operations officer at Terns. "This designation from the FDA su

    4/27/26 8:05:00 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns, for $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. The ex

    4/24/26 6:45:00 AM ET
    $MRK
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gengos Andrew bought $39,283 worth of shares (10,000 units at $3.93), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/30/25 5:38:10 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Burroughs Amy L. bought $90,230 worth of shares (23,314 units at $3.87), increasing direct ownership by 98% to 47,083 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/25/25 6:08:58 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Gengos Andrew bought $57,082 worth of shares (15,000 units at $3.81) (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/16/25 6:05:21 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    SEC Filings

    View All

    SEC Form 15-12G filed by Terns Pharmaceuticals Inc.

    15-12G - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    5/15/26 9:00:02 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.

    SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    5/13/26 9:19:15 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.

    SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    5/12/26 11:11:04 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Azelby Robert to satisfy tax liability

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    5/5/26 5:08:07 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Turner Heather D (tax withholding)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    5/5/26 5:07:07 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Tripuraneni Radhika (tax liability)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    5/5/26 5:06:03 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Leadership Updates

    Live Leadership Updates

    View All

    Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

    FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor

    2/24/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

    FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa

    2/20/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

    FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide

    11/18/24 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Financials

    Live finance-specific insights

    View All

    Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

    Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck's oncology pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN). "The Terns acquisition reflects Merck's continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients," said Robert M. Davis, chairman and chief executive officer, Merck. "We believe TERN‑701 has the potential to become a differentiated treatment option for certain patients with chronic myeloid leu

    5/5/26 8:45:00 AM ET
    $MRK
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

    64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today a

    12/8/25 2:45:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We're thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1

    11/10/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 5:51:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Terns Pharmaceuticals downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Terns Pharmaceuticals from Buy to Neutral

    3/25/26 10:23:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Terns Pharmaceuticals from Neutral to Buy and set a new price target of $20.00

    11/4/25 8:12:25 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care